87 results
8-K
EX-99.1
RLAY
Relay Therapeutics Inc
2 May 24
Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
4:10pm
oRLY-2608 + fulvestrant data update in the second half of 2024
oRLY-2608 + fulvestrant + ribociclib initial safety data in the second half of 2024 … clinical trials of its product candidates; Relay Therapeutics’ ability to successfully demonstrate the safety and efficacy of its drug candidates
8-K
EX-99.1
RLAY
Relay Therapeutics Inc
22 Feb 24
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
4:10pm
oRLY-2608 + fulvestrant data update in the second half of 2024
oRLY-2608 + fulvestrant + ribociclib initial safety data in the second half of 2024 … results in connection with future clinical trials of its product candidates; Relay Therapeutics’ ability to successfully demonstrate the safety
8-K
EX-99.1
muw 2a7m2r5u
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
8-K
EX-99.2
fqtfuafi
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
424B7
32hntp1fif2qnv 45
16 Nov 23
Prospectus with selling stockholder info
4:16pm
8-K
EX-99.1
4kst xhiueowo
2 Nov 23
Relay Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Highlights
4:10pm
8-K
EX-99.2
lcz48obj t9gcdyz
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
EX-99.1
sxg0s zgvu6viho2d7x
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
m3vtx3ji
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
EX-99.1
87rdm3
8 Aug 23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:14pm
8-K
EX-99.2
jbbjo
8 Aug 23
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
4:14pm
8-K
EX-99.1
58msou
25 May 23
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
5:05pm
8-K
EX-99.1
c6kes8yo
4 May 23
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
4:10pm